Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Pathogenesis of virus-associated tumours


Our research projects aim at understanding the pathogenesis of cancers caused by an infection with the Epstein-Barr virus (EBV). We have started more recently to study the contribution of EBV to the development of the autoimmune disease multiple sclerosis (see specific chapter). Finally, we have developed a new immunotherapeutic approach that uses viral e.g., EBV antigens, to induce an immune response against malignancies.

The Epstein-Barr virus (EBV) induces cancers that are characterized both by their diversity and their geographic heterogeneous distribution. EBV is associated with malignant lymphomas, but also nasopharyngeal carcinomas and a subset of gastric carcinomas. Moreover, some of these tumors are found with an increased frequency in specific parts of the world. These include nasopharyngeal carcinomas in South-East Asia and Burkitt's lymphoma in Equatorial regions. We have proposed that these differences result from infection with different EBV strains that are unequally distributed around the world. This hypothesis is supported by our observation that EBVs isolated from nasopharyngeal or gastric carcinomas have a much stronger tropism for epithelial cells than viruses found in lymphomas (Tsai et al., Cell Reports 2015; Tsai et al., Oncotarget 2017). We will pursue these investigations by studying the properties of viruses isolated from patients with EBV-associated diseases with the aim of identifying specific properties. These projects require classical molecular virology methods, associated with large-scale genomics and bioinformatics approaches.

Epidemiological studies have shown that individuals who have very high antibody titres against EBV proteins involved in virus lytic replication, the process that leads to new virus progeny, have an increased risk of developing nasopharyngeal carcinoma. We have identified EBV strains that induce strong lytic replication and used them to study the contribution of lytic replication to cancer development (Tsai et al., Cell Reports 2015). By comparing the properties of this virus with those of a mutant that cannot replicate, we have found that the replicating viruses are more tumorigenic (Shumilov, Tsai et al., Nature Comm 2017). We found that the virus particles themselves induce centrosome overduplication and more generally genomic instability (See project 1). Importantly, these abnormalities can be induced by virus-like particles and are independent of the viral DNA. As the majority of the population is infected by EBV, this identifies a new risk factor for cancer development.

Although EBV is a tumor virus, only a minority of infected individuals develop tumors. This is due to a large extent to the ability of the immune system to control EBV-infected cells. This implies that the majority of the population can mount a very potent immune response against the virus. We have designed a new immunotherapeutic strategy that is based on this observation and in which T cells specific to EBV epitopes are used to kill tumor cells (Yu, Ilecka et al., Blood 2015). This strategy uses a new type of armed antibody that consists of fusion proteins between antibodies and EBV epitopes. These chimeric antibodies bind to tumor cells, lead to efficient and specific presentation of EBV-specific antigens at their surface and to their killing by EBV-specific T cells (See project 4).

Research projects

to top
powered by webEdition CMS